PROSPECT is an open-label, Phase II study evaluating the efficacy, safety, and pharmacokinetics of an investigational oral medicine called Tirabrutinib (ONO-4059), a Bruton’s tyrosine kinase (BTK) inhibitor, in patients with primary central nervous system lymphoma (PCNSL).
The PROSPECT study is for patients diagnosed with PCNSL, a primary central nervous system lymphoma which is a type of cancer originating from immune cells known as lymphocytes that develop in the brain and/or spinal cord (central nervous system).
There are currently no therapeutic products/treatments specifically approved for the treatment of PCNSL in the U.S., therefore, a new treatment option is needed for patients diagnosed with PCNSL and relapsed PCNSL. EBCI would like to thank ONO PHARMA USA, Inc. for investing in this disease area to help lead the U.S. in exploring effective treatment options for this disease.
Additional information can be found at www.EndBrainCancer.org at the PROSPECT TRIAL/ONO PHARMA USA web landing page as well as at https://www.prospectstudy.com, which also offers an online “pre-screener” for this trial.
Dr. Daniela Bota, the Study Principal Investigator (PI) may be contacted at 714-456-7214 or at email@example.com for more information and to see if you are eligible to enroll into this clinical trial for the treatment of PCNSL. This study is currently recruiting 39 more patients in the U.S.
Dellann Elliott Mydland
President & Board Chair
The EndBrainCancer Initiative | Chris Elliott Fund